Categories: New Launches

SCHOTT on a successful course

 

  • Fiscal year 2013/2014: Global sales rose by 4% adjusted for currency effects
  • Comprehensive change process within the group aimed at achieving profitable growth
  • Promising growth and innovative products expected in India this year
Mumbai, Feb 21, 2015: SCHOTT AG continued on its growth course in fiscal year 2013/2014 (October 1, 2013, to September 30, 2014) by improving on all of its earnings indicators. EBIT amounted to EUR 135 million and was thus significantly higher than the EUR 74 million the company reported in fiscal year 2012/2013. Net profit for the year of EUR 66 million (EUR 25 million) and operating cash flow of EUR 182 million (EUR 151 million) also improved considerably. “In general, we are quite satisfied with the fiscal year that just ended. We managed to achieve the goals that we had set despite the negative influences of currency effects,” Dr. Frank Heinricht, Chairman of the Board of Management, emphasized at the annual results press conference recently.
Adjusted for significant exchange rate effects, the company increased its sales by 4%. Foreign sales continue to account for 86% of total sales. SCHOTT generates nearly half of its sales in Europe and one quarter each in North and South America and Asia.
SCHOTT India through its manufacturing sites in Gujarat and two sales offices in Mumbai and Pune also saw promising growth in the fiscal year 2013-2014. Main business for the sales office came from Advanced Optics, Electronic Packaging, Glass Ceramics and Flat Glass for Home Appliances and technical tubing.
SCHOTT’s join venture in India, SCHOTT KAISHA earned business through its market leading products such as Type I tubular glass prefillable syringes, cartridges, vials and ampoules which picked up significantly.
Fiscal year 2014/2015: Further growth planned
SCHOTT intends to continue on its course to sustainable and profitable growth in fiscal year 2014/2015 by increasing its worldwide group sales and EBIT by 2 to 3%. Investments in fixed assets are also projected to rise to EUR 150 million.

Specifically for the Indian market, SCHOTT KAISHA is planning to launch some high-end, innovative products, which will be disclosed soon. “Our target for this year, where we complete 25 years of operation, is to upgrade the existing technology at PR no.: 003/2015 Page 2 of 2 our plant in Jambusar, Gujarat, to enhance quality and output of its production,” said Mr. Kairus Dadachanji, Managing Director of SCHOTT KAISHA.CCI Newswire

The Pharma Times News Bureau

Recent Posts

The future of healthcare: Five key trends for providers in 2025

By Srinath Rao, Senior Vice President, CitiusTech A few decades back, the purpose of watches…

1 day ago

Switzerland’s Basel Region Crowned ‘Europe’s Top Destination to Launch a Drug Device Company’, According to Pharmapack Report

Pharmapack Europe: 'Basel the best location for drug device innovation in Europe thanks to combination…

1 day ago

Quote on HMPV by Doctors of Super Specialty Hospitals

New Delhi, January 07, 2025: HMP virus can travel to the brain, or it can…

2 days ago

Advisory For Hmpv – Key Preventative Measures

~ Co-authored by Dr Sanjith Saseedharan, Director-Critical Care, S. L. Raheja Hospital- A Fortis Associate…

2 days ago

40% of Doctor Appointments Dedicated to Family and Friends, Reveals MediBuddy’s 2024 Data

Patients Embrace Flexibility with 37% of Online Doctor Consultations now happening even After 6 PM,…

3 days ago

American Institute of Pathology & Laboratory Sciences (Ampath) in Collaboration Expands its Diagnostic Services in Uttar Pradesh

Launches Advanced Pathology Laboratory Offering Over 2500+ Tests in collaboration with Parashar Pathology Clinic in…

3 days ago